FDA Places Clinical Hold on Merck ' s Combo Therapy for Multiple Myeloma FDA Places Clinical Hold on Merck ' s Combo Therapy for Multiple Myeloma

Merck and Co Inc said on Wednesday the U.S. Food and Drug Administration had placed a clinical hold on three multiple myeloma studies testing its immunotherapy drug, Keytruda (pembrolizumab), in combination with other therapies.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news